Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
US11059891B2 · kind B2 · utility
1Cited by
13References
63Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 5, 2017 |
| Grant date | Jul 13, 2021 |
| Priority date | — |
| Expiry date | Jul 14, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/203
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.